Brief: Inhibikase Therapeutics Announces Closing Of $10 Million Concurrent Registered Direct Offering And Private Placement Priced At A Premium To Market Under Nasdaq Rules
27/01/2023 22:48
Jan 27 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES CLOSING OF $10 MILLION
CONCURRENT REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT
PRICED AT A PREMIUM TO MARKET UNDER NASDAQ RULES
Source text for Eikon: ID:nPn35m5Sxa
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share